Compare Citius Pharmaceuticals Inc (CTXR) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Thomson Reuters Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Thomson Reuters Corp trades at $103.08 (market cap $43.89B). The key difference: Thomson Reuters Corp is far larger — about 3222.5× Citius Pharmaceuticals Inc's market cap, and Thomson Reuters Corp pays a 2.58% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Thomson Reuters Corp for 63 Days on average.
| CTXR | TRI | |
|---|---|---|
Market Cap | $13.62M | $43.89B |
Volume | 132,438 | 1,648,199 |
Sector | Health | Industrials |
52-Week High | $1.82 | $163.45 |
52-Week Low | $0.48 | $76.55 |
Typical Hold Time | 17 Days | 63 Days |
Enterprise Value | $3.79M | $46.51B |
Dividend Yield | — | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Thomson Reuters (TRI) trades at $103.21, up 3.96% today, showing strong momentum near resistance at $103. The stock maintains robust fundamentals with 10% organic growth in core businesses and a 21.22% net income margin. Recent strategic moves include divesting the printing unit to focus on technology and launching a proprietary AI model, positioning for future growth. Technical indicators show bullish momentum with the current price approaching key resistance levels.
The outlook remains positive with analyst consensus targeting $133.25 (29% upside), supported by recurring revenue strength and AI expansion. Risks include cybersecurity incidents and execution challenges in tech transformation. With 52% of analysts rating Buy and strong institutional interest, TRI presents a growth opportunity tempered by valuation concerns at current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
